diff --git a/content/analysis_18f-fmpep-d2.html b/content/analysis_18f-fmpep-d2.html
index 4a4e3deab4a84ca6d15a9ef866dd1990b7b61c68..268d0233b8e32a98ca8e2d51420874439c36c063 100644
--- a/content/analysis_18f-fmpep-d2.html
+++ b/content/analysis_18f-fmpep-d2.html
@@ -1,7 +1,7 @@
 ---
 title: Analysis of PET measurements of [F-18]FMPEP-d2
 author: Vesa Oikonen
-updated_at: 2022-12-02
+updated_at: 2023-09-28
 created_at: 2015-09-23
 tags:
   - CB1R
@@ -16,7 +16,8 @@ tags:
 the <a href="./target_cannabinoids.html">endocannabinoid system</a>.
 Automated GMP-compliant synthesis device can produce adequate amounts of 
 [<sup>18</sup>F]FMPEP-<em>d<sub>2</sub></em> for multiple clinical studies per batch with high
-molar activity (<a href="https://doi.org/10.1002/jlcr.3845">Lahdenpohja et al., 2020</a>).</p>
+molar activity (<a href="https://doi.org/10.1002/jlcr.3845">Lahdenpohja et al., 2020</a>;
+<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509289/">Jiang et al., 2023</a>).</p>
 
 <p>[<sup>18</sup>F]FMPEP-<em>d<sub>2</sub></em> has high affinity and selectivity for 
 the CB<sub>1</sub>R, and since it also can pass